New treatments for Ewing sarcoma using SIRT5 inhibitors
Official title: SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma
Funded at University of Miami School of Medicine · NIH-11005706 · Data updated 2026-11-12
This study is exploring new ways to treat Ewing sarcoma, a tough cancer that mostly affects kids and young adults, by looking at how blocking a specific protein called SIRT5 can help kill cancer cells and improve treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1 |
| NIH project number | 5R01CA253986-04 |
| Project ID | NIH-11005706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and young adults diagnosed with Ewing sarcoma, especially those with advanced stages of the disease.
✕Less likely to help
Patients with other types of cancers or those who do not have Ewing sarcoma may not benefit from this research.
What this research studies
This research investigates the potential of SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma, a type of aggressive cancer primarily affecting children and young adults. The approach focuses on targeting the SIRT5 protein, which plays a crucial role in cancer cell survival. By depleting SIRT5, the researchers aim to induce apoptosis, or programmed cell death, specifically in Ewing sarcoma cells, potentially leading to improved treatment outcomes. The study will involve laboratory experiments to assess the effectiveness of these inhibitors in preclinical models of Ewing sarcoma.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients with Ewing sarcoma, particularly those with metastatic or recurrent disease.
How similar studies have gone: While the specific approach targeting SIRT5 in Ewing sarcoma is novel, similar strategies targeting other cancer-related proteins have shown promise in previous studies.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Lombard, David Benner — University of Miami School of Medicine
- Study coordinator: Lombard, David Benner
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.